METAVIA INC (MTVA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.75-4.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MTVA
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(18.5) + peer(0.2*-3.3) + term(0.0) → 5.8% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
and Item 7.01, respectively, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to th…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
and Item 7.01, respectively, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to th…
and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.. Forward-Looking Statements Exhibit 99.1 attached hereto contain forward-looking statements within the meaning…
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any informat…
and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements Exhibit 99.1 attached hereto contain forward-looking statements within the meaning…
and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements Exhibit 99.1 attached hereto contain forward-looking statements within the meaning…
and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements Exhibit 99.1 attached hereto contain forward-looking statements within the meaning…
Results of Operations and Financial Condition. On March 20, 2025, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2024 and providing a corporate update . A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to
Results of Operations and Financial Condition. On November 7, 2024, NeuroBo Pharmaceuticals, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2024 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by refere…
Results of Operations and Financial Condition. On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2024 and providing a corporate strategic update. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or…
Results of Operations and Financial Condition. On May 9, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a corporate strategic update. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 h…
Results of Operations and Financial Condition. On March 28, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the year ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purpose…